Christopher Jerdonek
Research Subjects
Christopher Jerdonek has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Min Brian Chiu
Ventric Health
2 shared publications - Weiwei Jin
Ventric Health, 117 E Colorado Blvd., Suite 510, Pasadena, CA 91105, USA
2 shared publications Asia Krupa
Ventric Health
1 shared publication- Asia Krupa
Ventric Health, 117 E Colorado Blvd., Suite 510, Pasadena, CA 91105, USA
1 shared publication Daniel LaMont
South Orange County Cardiology Group
1 shared publication- David M. Shavelle
Long Beach Medical Center, Long Beach, CA, USA
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (16) , 2629
Diagnostic Performance of Guideline-Recommended B-Type Natriuretic Peptide Thresholds for Detecting Elevated Left Ventricular End-Diastolic Pressure
Background : B-type natriuretic peptide (BNP) is widely used in the diagnosis, risk stratification, and management of heart failure (HF). However, its diagnostic performance for detecting elevated left ventricular filling pressure, particularly at lower thresholds, remains uncertain. Left ventricular end-diastolic pressure (LVEDP), measured during cardiac catheterization, provides direct evidence of abnormal left ventricular filling pressure and is a well-established indicator for HF. This study evaluated the diagnostic performance of guideline-recommended BNP thresholds for detecting elevated LVEDP. Methods: Data were analyzed from 154 patients referred for left heart catheterization (mean age, 66 ± 10 years; 64% male). LVEDP was measured directly using Millar Mikro-Tip pressure catheters. BNP was measured during the same visit. At a BNP threshold of 35 pg/mL, sensitivities for detecting LVEDP >15, >20, and >25 mmHg were 74%, 88%, and 92%, respectively, with corresponding specificities of 48%, 47%, and 42%. Results: At a BNP threshold of 100 pg/mL, sensitivities were 43%, 63%, and 75%, respectively, with corresponding specificities of 74%, 75%, and 71%. The corresponding areas under the receiver operating characteristic curve were 0.65, 0.75, and 0.81 for LVEDP >15, >20, and >25 mmHg, respectively. Conclusions: BNP demonstrated greater diagnostic accuracy at higher LVEDP thresholds but had limited sensitivity at lower thresholds, which may reduce its ability to detect hemodynamic abnormalities relevant to the evaluation of Stage B HF. BNP should therefore be interpreted in the context of a broader clinical assessment and additional diagnostic findings, particularly when the goal is to identify patients with less pronounced elevations in filling pressure.
- 19 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (16) , 2629
Open AccessDiagnostic Performance of Guideline-Recommended B-Type Natriuretic Peptide Thresholds for Detecting Elevated Left Ventricular End-Diastolic Pressure
Background : B-type natriuretic peptide (BNP) is widely used in the diagnosis, risk stratification, and management of heart failure (HF). However, its diagnostic performance for detecting elevated left ventricular filling pressure, particularly at lower thresholds, remains uncertain. Left ventricular end-diastolic pressure (LVEDP), measured during cardiac catheterization, provides direct evidence of abnormal left ventricular filling pressure and is a well-established indicator for HF. This study evaluated the diagnostic performance of guideline-recommended BNP thresholds for detecting elevated LVEDP. Methods: Data were analyzed from 154 patients referred for left heart catheterization (mean age, 66 ± 10 years; 64% male). LVEDP was measured directly using Millar Mikro-Tip pressure catheters. BNP was measured during the same visit. At a BNP threshold of 35 pg/mL, sensitivities for detecting LVEDP >15, >20, and >25 mmHg were 74%, 88%, and 92%, respectively, with corresponding specificities of 48%, 47%, and 42%. Results: At a BNP threshold of 100 pg/mL, sensitivities were 43%, 63%, and 75%, respectively, with corresponding specificities of 74%, 75%, and 71%. The corresponding areas under the receiver operating characteristic curve were 0.65, 0.75, and 0.81 for LVEDP >15, >20, and >25 mmHg, respectively. Conclusions: BNP demonstrated greater diagnostic accuracy at higher LVEDP thresholds but had limited sensitivity at lower thresholds, which may reduce its ability to detect hemodynamic abnormalities relevant to the evaluation of Stage B HF. BNP should therefore be interpreted in the context of a broader clinical assessment and additional diagnostic findings, particularly when the goal is to identify patients with less pronounced elevations in filling pressure.
- Open Access
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e040879
Screening Patients for Elevated Left Ventricular End‐Diastolic Pressure Using a Novel Noninvasive Brachial Cuff–ECG System: A Multicenter Validation Study
Background: Measurement of left ventricular end‐diastolic pressure (LVEDP) is an established diagnostic method to evaluate heart failure but requires an invasive procedure. A noninvasive technique for detecting elevated LVEDP would improve the diagnosis of heart failure. Herein, we present the results of a multicenter study to validate a noninvasive system to detect elevated LVEDP. Methods: The Vivio System includes a modified blood pressure cuff and single‐lead ECG to capture brachial artery waveforms. A model was created to identify patients with elevated LVEDP (>18 mm Hg). For the invasive cohort, all patients were referred for coronary angiography and left heart catheterization for clinical indications. A group of 321 patients with no significant health problems were enrolled as a control cohort. Invasive LVEDP measurements were performed using Millar catheters. The training data set (n=262) contained 101 patients with LVEDP measurements (n=44 with LVEDP >18 mm Hg) and 161 controls. The validation data set (n=155) contained 75 patients with LVEDP measurements (n=40 with LVEDP >18 mm Hg) and 80 controls. Results: Leave‐one‐out cross‐validation on the training data set yielded a sensitivity of 0.84 (95% CI, 0.70–0.93]) and a specificity of 0.84 (95% CI, 0.79–0.89). The validation data set showed a sensitivity of 0.80 (95% CI, 0.64–0.91) and a specificity of 0.83 (95% CI, 0.75–0.90). Conclusions: The Vivio System can accurately detect elevated LVEDP and has the potential to significantly improve early detection of heart failure in the outpatient setting.
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e040879
Open AccessScreening Patients for Elevated Left Ventricular End‐Diastolic Pressure Using a Novel Noninvasive Brachial Cuff–ECG System: A Multicenter Validation Study
Background: Measurement of left ventricular end‐diastolic pressure (LVEDP) is an established diagnostic method to evaluate heart failure but requires an invasive procedure. A noninvasive technique for detecting elevated LVEDP would improve the diagnosis of heart failure. Herein, we present the results of a multicenter study to validate a noninvasive system to detect elevated LVEDP. Methods: The Vivio System includes a modified blood pressure cuff and single‐lead ECG to capture brachial artery waveforms. A model was created to identify patients with elevated LVEDP (>18 mm Hg). For the invasive cohort, all patients were referred for coronary angiography and left heart catheterization for clinical indications. A group of 321 patients with no significant health problems were enrolled as a control cohort. Invasive LVEDP measurements were performed using Millar catheters. The training data set (n=262) contained 101 patients with LVEDP measurements (n=44 with LVEDP >18 mm Hg) and 161 controls. The validation data set (n=155) contained 75 patients with LVEDP measurements (n=40 with LVEDP >18 mm Hg) and 80 controls. Results: Leave‐one‐out cross‐validation on the training data set yielded a sensitivity of 0.84 (95% CI, 0.70–0.93]) and a specificity of 0.84 (95% CI, 0.79–0.89). The validation data set showed a sensitivity of 0.80 (95% CI, 0.64–0.91) and a specificity of 0.83 (95% CI, 0.75–0.90). Conclusions: The Vivio System can accurately detect elevated LVEDP and has the potential to significantly improve early detection of heart failure in the outpatient setting.